FDA gives Tagrisso 1st line status



AstraZeneca said Thursday the US Food and Drug Administration approved its lung cancer treatment Tagrisso for the first-line treatment of patients with metastatic non-small cell lung cancer. The approval comes after the results of the phase III FLAURA trial, showed Tagrisso met the primary endpoint. ‘Today’s FDA approval of Tagrisso in the 1st-line setting is an exciting milestone for patients and our company. Tagrisso delivered unprecedented medianprogression-free survival data across all pre-specified patient subgroups, including patients with or without CNS metastases, and could prolong the lives of more patients without their tumours growing or spreading,’ said Dave Fredrickson, Executive Vice President, Head of the Oncology Business Unit at AstraZeneca. Story provided by StockMarketWire.com